Registration for a live webinar on 'Phasing Out Animal Testing: A New Era for Pharmaceutical Innovation' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- What this talk will cover
- What this talk will not cover
- Lifetime chance of getting cancer
- UK cancer statistics
- Paradigm #1
- The beginnings of chemotherapy
- Advances in genomic biology has improved our understanding of cancer
- Understanding cancer pathways
- Early 2000s: targeted therapy era
- Acquired resistance to targeted therapy
- Hallmarks of cancer
- Germline mutations vs. somatic mutations
- Singapore’s Mass Rapid Transport (MRT) map
- Bulk RNA sequencing
- Single cell RNA sequencing
- Spatial profiling
- Components of the TME
- History of immunotherapy evolution
- Steady state of an evolutionary arms race
- Checkpoint blockade
- Paradigm shift #1
- Paradigm #2
- Surgery for cancer therapy
- Surgery to ‘cure’ cancer
- Adjuvant and neoadjuvant therapy
- Total neoadjuvant therapy for rectal cancer
- Paradigm shift #2
- Paradigm #3
- Clinical case 1
- Clinical case 2
- MMR deficient colon cancer – KEYNOTE 177
- 1-, 5- and 10-year survival of most common cancers
- Paradigm shift #3
- Concluding remarks
- Thank you
Topics Covered
- Cancer therapy and the immune system
- Chemotherapy and radiotherapy
- History of cancer treatment
- Advances in cancer therapy
- Acquired resistance to cancer therapy
- Cancer cells hijack cellular pathways
- Targeted cancer therapy
- Sequencing
- Cancer cells and the tumour microenvironment
- Immunotherapy
- Surgery and cancer treatment
- Adjuvant and neoadjuvant therapy
- Total neoadjuvant therapy
- Stage IV cancer
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Sundar, R. (2025, March 31). Harnessing the immune system for cancer therapy [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 3, 2025, from https://doi.org/10.69645/JHNS2230.Export Citation (RIS)
Publication History
- Published on March 31, 2025
Financial Disclosures
- Advisory board Bristol Myers Squibb, Merck, Eisai, Bayer, Taiho, Novartis, MSD, GSK, DKSH, Astellas, Pierre-Fabre, Tavotek, Astra Zeneca, Sanofi, Daichii Sankyo, Beigene Honoraria for talks MSD, Eli Lilly, BMS, Roche, Taiho, Astra Zeneca, DKSH, Ipsen, Daiichi Sankyo, Beigene, Astellas Travel Roche, Astra Zeneca, Taiho, Eisai, DKSH, Ipsen, CytoMed, Paxman Research funding Paxman Coolers, MSD, Natera, CytoMed Patents Paxman, Auristone
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Good day. I'm Raghav Sundar.
I'm an associate professor at
the National University
of Singapore and
also a senior consultant
medical oncologist
at the National University
Cancer Institute of Singapore.
Today, I'll be sharing
with you a topic
titled "Harnessing the Immune
System for Cancer Therapy".
0:22
These are my disclosures.
0:25
Today, I'm going to be
talking to you about some of
the paradigm shifting
changes that
have occurred in oncology
in the past decade.
0:34
However, what I will
not cover today are
the theories about how to treat
and manage individual cancers.
I must say though that as
a gastrointestinal
oncologist specializing in
treating patients with
colon cancer, stomach,
and esophageal cancers,
as well as
hepato-pancreatic-biliary cancers,
a lot of the examples
that I will show
today might lean towards
these tumor types.
But what is more
important to take
note is that these are examples
and proof of principles
of some of the
concepts I'm going to try
and bring about today.
1:10
Many of us know that getting
cancer is very common.
However, what may not be
common knowledge is the
fact that actually,
the lifetime chance
of getting cancer in
men is one in two and for
women is one in three.
This can be potentially
very scary thinking
about half of us as men might
get cancer and a third of us as
women might end up getting
cancer sometime
during our lifetime.
1:38
However, everything is
not all that dismal.
While it is true that
one in two of us
might be diagnosed with
cancer in our lifetimes,
more of us are beating
cancer than ever before.
Survival rate for
cancer patients over
the past 20 or 30 years has
more than doubled
and today, I will be
sharing with you a little bit
about why this is happening.